CIK 0001001233
- Non-accelerated filer
- Smaller reporting company
SANGAMO THERAPEUTICS, INC
Sign in to watch- Ticker
- SGMOQ
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680359556
- Phone
- +1 510-970-6000
- Business address
- 501 CANAL BLVD., RICHMOND, CA, 94084
- Former names
- SANGAMO BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-25 | Jain Nikunj Principal Accounting Officer | Shares withheld for taxes | −1,919 | $0.17 | $334 | 235,292 |
| 2026-05-25 | Davis Gregory D Head of Research & Technology | Shares withheld for taxes | −1,630 | $0.17 | $284 | 113,654 |
| 2026-05-25 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Shares withheld for taxes | −4,036 | $0.17 | $703 | 328,733 |
| 2026-05-25 | Willoughby Scott B. SVP, CHIEF LEGAL OFFICER, SECY | Shares withheld for taxes | −4,036 | $0.17 | $703 | 647,370 |
| 2026-05-25 | Macrae Sandy PRESIDENT, CEO AND DIRECTOR | Shares withheld for taxes | −12,613 | $0.17 | $2K | 1,895,043 |
| 2026-04-22 | Davis Gregory D Head of Research & Technology | Sale | −69,827 | $0.25 | $18K | 115,284 |
| 2026-04-21 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Sale | −345,942 | $0.26 | $89K | 332,769 |
| 2026-04-01 | Jain Nikunj Principal Accounting Officer | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2026-04-01 | Davis Gregory D Head of Research & Technology | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2026-04-01 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Grant or award · Stock Option (Right to Buy) | +800,000 | 800,000 | ||
| 2026-04-01 | Willoughby Scott B. SVP, CHIEF LEGAL OFFICER, SECY | Grant or award · Stock Option (Right to Buy) | +800,000 | 800,000 | ||
| 2026-04-01 | Macrae Sandy PRESIDENT, CEO AND DIRECTOR | Grant or award · Stock Option (Right to Buy) | +2,500,000 | 2,500,000 | ||
| 2026-02-25 | Jain Nikunj Principal Accounting Officer | Shares withheld for taxes | −5,119 | $0.47 | $2K | 237,211 |
| 2026-02-25 | Davis Gregory D Head of Research & Technology | Shares withheld for taxes | −5,119 | $0.47 | $2K | 185,111 |
| 2026-02-25 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Shares withheld for taxes | −12,354 | $0.47 | $6K | 678,711 |
| 2026-02-25 | Willoughby Scott B. SVP, CHIEF LEGAL OFFICER, SECY | Shares withheld for taxes | −12,354 | $0.47 | $6K | 651,406 |
| 2026-02-25 | Macrae Sandy PRESIDENT, CEO AND DIRECTOR | Shares withheld for taxes | −33,637 | $0.47 | $16K | 1,907,656 |
| 2026-02-24 | Jain Nikunj Principal Accounting Officer | Shares withheld for taxes | −666 | $0.47 | $315 | 242,330 |
| 2026-02-24 | Davis Gregory D Head of Research & Technology | Shares withheld for taxes | −832 | $0.47 | $393 | 190,230 |
| 2026-02-24 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Shares withheld for taxes | −2,063 | $0.47 | $975 | 691,065 |
Page 1 of 9 · 165 trades